SCHEMBL5849008

SCHEMBL5849008

Clc1nc(Cl)c(Cl)nc1Cl

nearest known ligand 0.46

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.46
ALOX15 P16050 1/20 0.46
TSHR P16473 1/20 0.46
TDP1 Q9NUW8 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29209568 0.76 TDP1 (0.32) TDP1
SCHEMBL1732884 0.76 ALDH1A1 (0.37) ALDH1A1TSHRTDP1
SCHEMBL468366 0.75 ALDH1A1 (0.36) ALDH1A1ALOX15TSHRTDP1
Potassium SCHEMBL8421932 0.71 ALDH1A1 (0.33) ALDH1A1ALOX15TSHR
SCHEMBL30519310 0.71 TDP1 (0.35) ALDH1A1ALOX15TSHRTDP1
SCHEMBL25215909 0.71 TDP1 (0.35) ALDH1A1ALOX15TSHRTDP1
SCHEMBL9870212 0.71 NQO1 (0.39) ALDH1A1ALOX15TSHRTDP1
SCHEMBL11540011 0.69 TDP1 (0.56) ALDH1A1ALOX15TSHRTDP1
SCHEMBL2366051 0.69 TDP1 (0.41) ALDH1A1ALOX15TSHRTDP1
SCHEMBL10602509 0.69 NOD2 (0.42) ALDH1A1ALOX15TSHRTDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11780817-B2 Methods for preparing Favipiravir Weaver Labs, LLC (US) 2023-10-10 US claimed
US-20210355090-A1 METHODS FOR PREPARING FAVIPIRAVIR Weaver Labs, LLC (US) 2021-11-18 US claimed
CN-112786880-A Diamond-shaped hole graphite monoalkyne derivative and preparation method and application thereof 复旦大学 2021-05-11 CN claimed
CN-105884794-A Preparation method and application of organic conjugated micro-molecules rich in nitrogen and sulfur 中国科学院化学研究所 2016-08-24 CN claimed
EP-4063358-B1 HISTONE METHYLTRANSFERASE INHIBITORS GLOBAL BLOOD THERAPEUTICS INC (US) 2024-05-22 EP disclosed
CN-118027012-A Organic compound and application thereof, ultraviolet light conversion packaging adhesive film, preparation method of ultraviolet light conversion packaging adhesive film and photovoltaic module 江苏绿人半导体有限公司 2024-05-14 CN disclosed
EP-4291565-A1 SYNTHETIC CINCHONA ALKALOIDS AGAINST CANCER Ares Pharmaceuticals, LLC (US) 2023-12-20 EP disclosed
US-11780817-B2 Methods for preparing Favipiravir Weaver Labs, LLC (US) 2023-10-10 US disclosed
US-11713299-B2 Histone methyltransferase inhibitors GLOBAL BLOOD THERAPEUTICS, INC. (US) 2023-08-01 US disclosed
WO-2023092781-A1 PREPARATION METHOD FOR REVERSE OSMOSIS MEMBRANE, AND REVERSE OSMOSIS MEMBRANE PREPARED THEREBY 沃顿科技股份有限公司 2023-06-01 WO disclosed
CN-116159449-A Method for preparing reverse osmosis membrane and reverse osmosis membrane prepared by same 沃顿科技股份有限公司 2023-05-26 CN disclosed
US-20230139809-A1 BENZIMIDAZOLE DERIVATIVES MERCK PATENT GMBH (DE) 2023-05-04 US disclosed
US-4372328-A Fibrous material for tobacco smoke filter B.A.T. CIGARETTEN-FABRIKEN GMBH (DE) 1983-02-08 US disclosed
US-4101546-A Cyanatothiomethylthio pyrazines THE DOW CHEMICAL COMPANY (US) 1978-07-18 US disclosed
US-4029657-A MICROBIOCIDAL, HERBICIDAL OR INSECTICIDAL INTERMEDIATES THE DOW CHEMICAL COMPANY (US) 1977-06-14 US disclosed
US-4029657-A MICROBIOCIDAL, HERBICIDAL OR INSECTICIDAL INTERMEDIATES THE DOW CHEMICAL COMPANY (US) 1977-06-14 US disclosed
US-4025510-A DYES FOR POLYESTERS E. I. DU PONT DE NEMOURS AND COMPANY (US) 1977-05-24 US disclosed
US-3987044-A SEPARATION OF 2,3-DIAMINO-DIHALOPYRAZINES FROM MIXTURES AS NOVEL ASSOCIATION PRODUCTS WITH CERTAIN KETONES THE DOW CHEMICAL COMPANY (US) 1976-10-19 US disclosed
US-3976644-A Method for preparing 2,5-dihalopyrazines THE DOW CHEMICAL COMPANY (US) 1976-08-24 US disclosed
US-3882116-A PREPARATION OF PERCHLORINATED HETEROCYCLIC COMPOUNDS DU PONT 1975-05-06 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780817-B2 Methods for preparing Favipiravir FBP1, PFAS, FUCA2 ALDH1A1 2888/4885ALOX15 1645/4885TSHR 4123/4885
US-20210355090-A1 METHODS FOR PREPARING FAVIPIRAVIR FBP1, PFAS, FUCA2 ALDH1A1 2888/4885ALOX15 1645/4885TSHR 4123/4885
US-20230139809-A1 BENZIMIDAZOLE DERIVATIVES ECI1, COX4I1, BRD4 ALDH1A1 148/4885ALOX15 3640/4885TSHR 4194/4885
US-11713299-B2 Histone methyltransferase inhibitors EHMT1, DOT1L, EHMT2 ALDH1A1 420/4885ALOX15 3245/4885TSHR 2480/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.